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Co-morbidity in a cystic fibrosis populafion attending a regional 
clinic 
F. Healy 1, M.J. Mahony 1, H. Coffey 1, E. Mul loy 2, T.H. Peirce 9
~Department of Paediatrics, Limerick Regional Hospital, Ir el ~ul,2Department of
Adult Respiratory Medicine, Limerick Regional Hospital, b ela~M
Aims:  We noted a significant number of cystic fibrosis (CF) patients attending a 
regional clinic had additional co morbid conditions including neoplasms, thus 
adding to their complex management. 
Methods:  ha October 2(104 we reviewed all 115 patients attending CF clinics ha 
L imerick Regional Hospital 42 adults and 73 attending paediatric services. We 
looked at the prevalence of additional medical diagnoses, excluding any recognised 
complications of CF. 
Results: We noted 16 cases (14%) with co morbid conditions. Most notably, 3 had 
neoplasms, including one 19 year old male with metastatic, poorly differentiated, 
adenc*zarcinoma of the ileccaecal valve. The second neoplasm was a stage 2 
testicular teratoma ha a 24 year old male. The third was a mature ovarian teratoma 
ha a 4 year old girl. 
ha addition, 4 cases had renal problems including ureterocele, IgA nepbropathy, 
duplex kidney and pelviureteric junction obstruction. 
4 patients were found to have neurological disorders including 3 female patients 
with epilepsy i.e. partial seizures, absence seizures and juveni le mycclonic epilepsy. 
The fourth case was a female with a left hemiplegia secondary to a right middle 
cerebral artery infarct. Other conditions included 1 each of developmental dysplasia 
of the hip, atrioseptal defect, phimosis, hepatit is B and attention deficit  
hyperactivity disorder. 
Conclusion: Of  115 patients attending a regional CF clinic, a significant number 
have co morbid conditions including 3 with neoplasms. This has an additional 
impact on their complex management aswel l  as pr o~aosis and life expectancy. 
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Cystic fibrosis and cancer relation 
L. Pop 1, I. Popa 1, Z. Popa 9, S. Turcu 1 
~Clinic H Pediatrics, University of Medicine wul Pharmacy ~misoara, 2CF Centre 
~rnisoara, Romania 
The permanent improvement of the management of CF, leads to a significant 
increase in the quality and life expectation ha these patients. In association to the 
wel l  known clinical polymorphism of the patients with CF a new problem is raising, 
respectively higher incidence of cancer, ha general, especially of some particular 
forms. The aim of study was the evaluation f the r isk cancer in CF patients from 
Romania. Study method: retrospective study of 20 CF adult patients (6 male and 14 
female) from CF Cenlre Timisora. Results: At the t ime of study 5 cases deceased 
(mean age 21, 4 years) and 15 alive (mean age 23,1 years). The genotype of 
deceased cases was: homozygote DF508 at 3 patients and compound heterozygote 
genotype at 2 cases. The genotype of al ive cases was: 3 cases with homozygote 
DF508, 10 cases compound heterozygote DF508 and 2 cases with DF508 and 
polymorphic allele. Mean age of our patients for the onset of a malignant status is 
superposed with literature data. Anyway specific investigations aiming for the 
detection of a form of cancer were negative in the studied lot. Conclusions: our 
results do not confirm the literature data, but we are not in the position to make any 
statistical considerations; remains for discussions the role of the exogenous factors, 
without a precise evaluation of these. 
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Lupus erythematosus and Cystic Fibrosis. Case report and screening 
in the CF-population 
J. Mainz, F. Ringelmann, D. Kemper, A. Huebler, J. DoembracK K. Dawczynski, E
Zintl  
CF-Centre for chiMren arm adults, University of Jena, Germany 
We report about the rare association of Cystic Fibrosis and lupus erythematosus ha
a 49 year s old woman genotype F508del/G85E and present the result s of a screening 
for antinuclear antibodies ha 50 CF patients. 
ha our patient CF diagnose was made in 1987 by tbree positive sweat tests (Ck 
>lCO mmol/l). At this t ime she had a history of recurrent pneumonia nd pulmonary 
colonisation w i th  mucoid Pseudomonas as we l l  as moderate pancreatic 
insufficiency. 
Since 1998 she complained about diffuse pain of muscles and joints. Initial ly 
shoulders and knees were involved; later she also suffered from pain and swell ing 
of the fingers. Exposition to stmlig)at provoked skin rashes; symptoms of erythema 
nodosum revealed on forearms and knees. 
Additionally to these clinical signs the fol lowing serum antibodies were found: 
ANA 1:5120, ds DNA 203 IU/ml, ss DNA 226 IU/ml, Histon antibodies 32 IU/ml  
and positive circulating immune complexes. The diagnose of lupus erythematoms 
was made as more than 5 of 11 diagnostic riteria defined by the American College 
of Rheumatology were fulfi l led. 
We screened our CF population to evaluate, whether cl inical or serological signs for 
lupus erythematosus occur frequently ha C~ys~ic Fibrosis. 
Results: In a 33 years old patient high antinuclear antibodies were found (ANA 
1:5120); two 17 and 38 years old patients had positive titres for ds DNA 
(40.2 IU/ml/27.9 IU/ml); one female adult patient suffered from CF arthritis. A l l  of 
these patients did not reveal further cl inical or serological criteria of lupus 
erythemat osus. 
Conclusion: We present he rare association of CF and lupus erythematosus not 
described in literature. The results of our screening point out the need of further 
investigation i this field. 
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taken from a "port"in patients with cystic fibrosis 
S. Satmder s 1, M. Tabberner 1,W. Nixon 1, M. Desai 1, V. Wil l iams 2, R. Raynet ° 
~Dept of Respiratory Medicine, Birmingham ChiMren's Hospital, Birmingham, 
2Department ofPaediatrics, Royal Wolverhampton Hospital, Wolverharr~ton U.K. 
Aims: To compare the results of Tobramycin blood levels from "ports" (totally 
implanted venous access devices) with those from capillary samples. I f  shown to be 
comparable, the use of "port" levels would save our patients another painful 
pr ccedure. Levels of other drugs e.g. Vancomycin are determined using blood from 
"ports". 
Methods: Al l  patients with CF who were receiving intravenous Tobramycin tbree 
times daily via a "port" were el igible for the study. After informed consent was 
obtained, paired "port" and capillary/venous samples were taken at the appropriate 
t ime during the antibiotic course. Blood was taken from the catheter ha situ 
immediately after the capillary sample was taken. Clinical decisions were taken on 
the capillary result as per normal. To avoid bias the "port" results were kept from 
the investigators making clinical decisions. 
Results: The study was discontinued after 11 paired samples from 11 children were 
obtained. The results showed very different levels in the paired samples with no 
correlation within the pairs. It was deemed unethical to continue. 
Conclusion: We conclude that using blood from a "port" is not a reliable method of 
checking Tobramycin levels. 
